Genomics

基因组学

基本信息

项目摘要

In this current age of genome biology, the primary objective of the Genomics Core is to accelerate the study of HIV and opportunistic infections associated with AIDS by providing researchers with access to genomic technologies. Examining host genetics following pathogen infection can identify new targets and pathways for drug development, reveal the genetic mechanisms of disease pathogenesis, determine predictive gene expression profiles that can guide treatment options, and identify single nucleotide polymorphisms (SNPs) associated with disease that can be used to judge the effectiveness of different antiviral drug therapies. To facilitate such research, the specific aims of the Genomics Core are as follows: (1) to provide researchers with a cost-effective mechanism to analyze mammalian gene expression at the whole genome level using microarray technology, (2) to enable the more precise quantification of both coding and non-coding gene expression using real-time quantitative RT-PCR (qRT-PCR), (3) to screen large numbers of samples for specific SNPs, and (4) to offer expertise and training in bioinformatics applications required to process and interpret the data generated by genomic technologies. The Genomics Core is currently outfitted with a suite of laboratory equipment to meet these aims (2 x ABI Prism 7700 Sequence Detection Systems, a Bio-Rad iCycler, an Affymetrix Fluidics Station 400 and a Sun Microsystems Sunfire 250 Enterprise server). Staff at the core are highly trained and skilled in areas of nucleic acid isolation, purification and quantification, and primer design, gene expression assays and bioinformatic analysis. In summary, the contribution of the Genomics Core to HIV- and AIDS-related research is best reflected by the numerous projects supported by the core, among which include the first assessment of HIV-stimulated gene expression in CD4 T cells, identification of pathways resulting in HIV induced apoptosis, the effects of methamphetamine use on HIV encephalitis, and identification of the amino acid polymorphisms that contribute to ritonavir hypersusceptibility. This proposal will allow the Genomics Core to continue bridging the gap between HIV-related research and genomic technologies in an economical manner. This will allow HIV research to benefit from the very latest developments in genome biology, which will ultimately translate into a better understanding of disease pathogenesis and the evolution of better therapies.
在这个基因组生物学的时代,基因组学核心的主要目标是加速 研究艾滋病毒和与艾滋病相关的机会性感染,为研究人员提供 基因组技术。病原体感染后检查宿主遗传学可以识别新的靶点和 药物开发途径,揭示疾病发病的遗传机制,确定 预测性基因表达谱,可以指导治疗方案,并识别单核苷酸 与疾病相关的多态(SNP)可用于判断不同 抗病毒药物疗法。为了促进这种研究,基因组学核心的具体目标如下: (1)为研究人员提供一种经济有效的机制来分析哺乳动物的基因表达 使用微阵列技术的全基因组水平,(2)使两者能够更精确地定量 编码和非编码基因表达的实时定量RT-PCR(qRT-PCR),(3)筛选 为特定SNP提供大量样本;以及(4)提供生物信息学专业知识和培训 处理和解释基因组技术产生的数据所需的应用程序。基因组学 CORE目前配备了一套实验室设备以实现这些目标(2个ABI棱镜7700 序列检测系统、Bio-Rad iCycler、Affymetrix Fluidics Station 400和Sun MicroSystems Sunfire 250企业版服务器)。核心员工在以下领域训练有素、技术娴熟 核酸的分离、纯化和定量,以及引物设计、基因表达分析和 生物信息学分析。总之,基因组学核心对艾滋病毒和艾滋病相关疾病的贡献 核心支持的许多项目最好地反映了研究,其中包括第一个 评估HIV刺激的CD4T细胞基因表达,确定导致HIV的途径 诱导细胞凋亡,使用甲基苯丙胺对HIV脑炎的影响,以及鉴定 导致利托那韦过敏反应的氨基酸多态。这项提议将允许 基因组学核心将继续弥合艾滋病毒相关研究和基因组技术之间的差距 经济实惠的方式。这将使艾滋病毒研究受益于基因组的最新发展。 生物学,这最终将转化为更好地理解疾病的发病机制和 更好的治疗方法的进化。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHRISTOPHER H WOELK其他文献

CHRISTOPHER H WOELK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHRISTOPHER H WOELK', 18)}}的其他基金

Synthetic Molecular Sensors to Target Latently Infected Cells for HIV Eradication
合成分子传感器瞄准潜在感染细胞以根除艾滋病毒
  • 批准号:
    8657164
  • 财政年份:
    2013
  • 资助金额:
    $ 25.04万
  • 项目类别:
Synthetic Molecular Sensors to Target Latently Infected Cells for HIV Eradication
合成分子传感器瞄准潜在感染细胞以根除艾滋病毒
  • 批准号:
    8463060
  • 财政年份:
    2013
  • 资助金额:
    $ 25.04万
  • 项目类别:
Synthetic Molecular Sensors to Target Latently Infected Cells for HIV Eradication
合成分子传感器瞄准潜在感染细胞以根除艾滋病毒
  • 批准号:
    8607892
  • 财政年份:
    2013
  • 资助金额:
    $ 25.04万
  • 项目类别:
Genomics Core
基因组学核心
  • 批准号:
    8326909
  • 财政年份:
    2011
  • 资助金额:
    $ 25.04万
  • 项目类别:
Gene expression biomarkers of immune recovery in HIV infected patients
HIV感染者免疫恢复的基因表达生物标志物
  • 批准号:
    7996540
  • 财政年份:
    2009
  • 资助金额:
    $ 25.04万
  • 项目类别:
Gene expression biomarkers of immune recovery in HIV infected patients
HIV感染者免疫恢复的基因表达生物标志物
  • 批准号:
    8196805
  • 财政年份:
    2009
  • 资助金额:
    $ 25.04万
  • 项目类别:
INTERFERON STIMULATED GENES WITH ANTIVIRAL PROPERTIES TO HIV-1
干扰素刺激基因具有抗 HIV-1 病毒特性
  • 批准号:
    8166821
  • 财政年份:
    2009
  • 资助金额:
    $ 25.04万
  • 项目类别:
Gene expression biomarkers of immune recovery in HIV infected patients
HIV感染者免疫恢复的基因表达生物标志物
  • 批准号:
    7840606
  • 财政年份:
    2009
  • 资助金额:
    $ 25.04万
  • 项目类别:
Genomics
基因组学
  • 批准号:
    7635790
  • 财政年份:
    2008
  • 资助金额:
    $ 25.04万
  • 项目类别:
INTERFERON STIMULATED GENES WITH ANTIVIRAL PROPERTIES TO HIV-1
干扰素刺激基因具有抗 HIV-1 病毒特性
  • 批准号:
    7950962
  • 财政年份:
    2008
  • 资助金额:
    $ 25.04万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 25.04万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 25.04万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 25.04万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 25.04万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 25.04万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 25.04万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 25.04万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 25.04万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 25.04万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 25.04万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了